Drug firm Wockhardt on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, ...

International business now contributes 77% to Wockhardt's revenue, with biosimilars clocking 30% on year growth in emerging ...

Wockhardt’s Q2 loss narrowed to ₹16 crore from ₹73 crore a year earlier, bolstered by a 7.4% revenue rise and expanded ...

Wockhardt's Q2 net loss shrinks to Rs 16 cr, with revenue reaching Rs 809 cr. Read about the company's financial performance and stock updates.

Through this QIP, Wockhardt said it aims to strengthen its capital structure, possibly funding growth initiatives or reducing ...

Wockhardt's equity dilution is pegged at 5.57% of post-issue paid up share capital, according to the term sheet.

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

Wockhardt hit a lower limit of 5% at Rs 1206.50 after the company launched a qualified institutional placement (QIP) at a floor price of Rs 1,162.25.

If you are quickly exhausted and find it difficult to control your frequent weight gains, you may have Hashimoto’s syndrome, ...

Wockhardt has been a wealth destroyer as its shares have underperformed Nifty 50 by over 150% over the last 10 years. However ...

Drugmaker Wockhardt has approached the Drug Controller General of India (DCGI) seeking approvals for its fast-acting insulin analog, Aspart injection. The company’s Aspart insulin injection ...